# A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102

> **NCT03636477** · PHASE1 · COMPLETED · sponsor: **Alaunos Therapeutics** · enrollment: 21 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **BIOLOGICAL:** Ad-RTS-hIL-12
- **DRUG:** veledimex
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03636477
- **Lead sponsor:** Alaunos Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-18
- **Primary completion:** 2020-10-15
- **Final completion:** 2021-06-30
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03636477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03636477, "A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT03636477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*